No way! But... [Design Issues]

posted by wienui  – Germany/Oman, 2019-12-07 04:01 (894 d 16:23 ago) – Posting: # 20955
Views: 5,230

(edited by wienui on 2019-12-07 06:47)

Dear all,

» So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)

I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,
Osama

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
22,085 posts in 4,629 threads, 1,566 registered users;
online 15 (0 registered, 15 guests [including 9 identified bots]).
Forum time: Thursday 21:24 CEST (Europe/Vienna)

That which is not controversial
is of no particular interest.    Johann Wolfgang von Goethe

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5